numerical rating scale. Another physician severity rating was performed with the Occupational Contact Dermatitis Disease Severity Index (ODDI), which includes an assessment of impairments in workrelated activities. 13, 14 The Erlangen atopy score was used to assess atopy. 15, 16 Six diagnostic categories were used to classify hand eczema, representing both aetiological (irritant contact dermatitis, allergic contact dermatitis [ACD] , and atopic HE) and morphological (vesicular dermatitis, hyperkeratotic dermatitis, and fingertip dermatitis) categories. HR-QoL was measured with the German version of the Dermatology Life Quality Index (DLQI). 17, 18 Because new research has shown that there are several limitations in using the DLQI in patients with CHE, we report adjusted DLQI scoring, which is assumed to be adequate in a population of CHE patients (only 6 items are scored, and the range of the adjusted DLQI is 0-15). 19 In order to overcome those limitations of the DLQI, the Quality of Life in Hand Eczema Questionnaire (QOLHEQ) 20 was later introduced into the registry. The QOLHEQ is a disease-specific HR-QoL instrument that assesses HR-QoL of HE patients in 4 domains: (1) symptoms, (2) emotions, (3) functioning, and (4) Figure S1 . 
| Sociodemographic characteristics at baseline

| Clinical characteristics at baseline
In the 12 months before inclusion in the CARPE registry, a patch test had been performed in 54.6% of all patients, and contact allergy was found in 48.5%. The most prevalent allergens were nickel (23.9%), fragrance mix I (16.9%), cobalt (13.6%), and chromium (12.9%). Whereas the 3 most common allergens were more prevalent in females, chromium was the only allergen that was more common in males. Table 2 shows the 10 most frequent contact allergies that were found to be of clinical relevance for CHE. Prick testing was performed in 42.3% of the patients. Immediate-type hypersensitivity to latex with clinical relevance for CHE was found in 5.4% (n = 30) of those who had been prick tested in the previous 12 months (n = 542).
Mycological diagnostic investigation was performed in 38.4% of the patients; the findings were negative in 81.4% of the tested patients, positive in 8.0%, and unclear in 10.7%. The most frequent localization was the palm of the hand (83.5%), followed by the interdigital web spaces (64.8%) and the back of the hand (48.6%). In the overwhelming majority of cases (96.1%), both hands were affected by CHE, in 2.8% CHE was localized to the right hand, and in only 0.8% CHE was localized to the left hand. Concomitant eczema on the feet was present in 27.3% of the patients; eczema at other body sites was present in 23.6%. Itching was present in 80.1% of the patients.
Females reported moderate or severe itching more often than males (50.7% vs 42.4%).
Irritant contact dermatitis was the most frequent diagnosis, seen in 583 patients (45.5%), followed by atopic HE (35.8%), hyperkeratotic-rhagadiform HE (32.1%), vesicular HE (25.8%), ACD (21.1%), and fingertip dermatitis (7.2%). An atopic skin diathesis was present in 43.5% of the patients, was absent/unlikely in 46.8%, and was uncertain in 9.7%. As can be seen in Table 3 , the most common skin-stressing exposures were wet work and wearing gloves. Overall, 78.6% of the patients were using gloves at work, at leisure time, or in both settings.
| Medication
Overall, 51.2% of the patients had received topical corticosteroid treatment at the time of their first CARPE visit (T 0 ), 23.1% with potent corticosteroids and 5.9% with very potent corticosteroids. Figure S2A shows the course of topical treatment with corticosteroids during the course of the CARPE registry. At T 8, only 29.9% of the patients had received a prescription of topical corticosteroids. The course of any other topical therapy during the CARPE registry is shown in Figure S2B . The rates of prescription of urea (35.2% at T 0 ) and tannin (22.0% at T 0 ) rose slightly until T 8 (47.3% and 32.0%, respectively).
The prescription of salicylic acid fell from 9.4% at T 0 to 3.6% at T 8 .
The rates of UV therapy prescription are shown in Figure S2C . The strongest decrease was found in the prescription of psoralen plus UVA (PUVA) cream, which decreased from 23.0% at T 0 to 2.5% at T 8 .
The prescription rate for bath PUVA and for other light therapies was <2.0%, and the prescription of other systemic PUVA therapies was negligible. The prescription rate for any systemic therapy during the CARPE registry is shown in Figure S2D . It can be seen that the prescription of any systemic therapy declined from 31.1% at T 0 to 13.5% at T 8 . Overall, n = 499 patients (39.0%) were treated with alitretinoin, acitretin or methotrexate during the course of the CARPE registry.
| Response analysis
Because a relevant number of patients were lost to follow-up, we performed a responder/non-responder analysis in relation to baseline characteristics of the sample. The analysis was performed for the response until the regular follow-up after 2 years (T 5 ) and until the end of the extended follow-up after 5 years (T 8 ). The results are shown in Table S2 . We found no significant differences between responders and non-responders concerning sex, age, severity of HE (PGA), or HR-QoL (DLQI). However, the proportion of patients with a notified occupational disease was higher in the responder group at 
| Adverse events
Over the whole 5-year period, 128 patients reported at least 1 adverse event related to a prescription drug. Of those adverse events, 56.5%
were reported to be mild, 35.7% moderate, and 7.8% severe. In 45.4%, the adverse event was likely to be associated with a specific drug, and for 27.1% of the events this association was confirmed.
Most of the adverse events were seen to be associated with alitretinoin (73.0%) or ciclosporin (12.8%).
| Severity of CHE and HR-QoL impairment
As shown in Figure 1 , the majority of CHE patients had moderate (45.9%) or severe (22.4%) skin lesions at the time of inclusion in the CARPE registry according to PGA. The severity decreased steadily down to a level of 17.9% moderate cases and only 2.2% severe cases at T 8 . At the same time, the patients' self-rated severity (on a scale from "0: no lesions" to "10: very severe lesions") declined from a mean severity of 4.9 (SD 2.5) to a value of 2.4 (SD 2.2) (Figure 2 ). The selfrated severity decreased from 4.9 (SD 2.7) to 3.9 (SD 2.2) at 3-month follow-up, and followed a linear trend, decreasing to 3.6 (SD 2.3) at Table 4 .
Disease severity as assessed with the ODDI ( Figure S3A ) showed a similar course as assessed with PGA. Impairments in work-related activities decreased, as can be seen in Figure S3B : at T 0 , only 3.8% of the patients reported no work-related limitations, but this proportion increased to 42.1% at T 8 , whereas the proportion of patients with According to the definition of Hongbo et al, 21 in 308 patients (27.8%) the CHE had a very large effect on HR-QoL, and in 63 (5.0%) the effect was extremely large at the time of inclusion in the CARPE registry. According to the QOLHEQ, the HR-QoL impairments were strongest in the areas of symptoms (mean 25.5) and functional (mean 26.1) impairments, whereas impairments because of emotions (mean 5.2) and because of treatment and prevention (mean 15.5) were less intense.
As shown in Figure S4A , the number of patients reporting sideeffects declined during the course of the CARPE registry. Also the amount of patients who reported the treatment to be time-consuming declined ( Figure S4B ). Figure S4C shows that treatment satisfaction increased until T 7 and then was quite stable at T 8 . Interestingly, the number of patients reporting not being able to perform treatment according to recommendations increased during the course of the CARPE registry ( Figure S4D ). The number of visits to a dermatologist in the past 12 months decreased strongly after inclusion into the CARPE registry, and was then quite stable ( Figure 3 ). The same trend was seen regarding visits to a general practitioner (data not shown). ), both as rated by the patient, with 95%CIs time, with data collected for all topical, UV and systemic therapies, and an assessment of disease burden from both the doctors' and patients' perspectives.
| DISCUSSION
There were significant differences between responders and nonresponders at T 5 and T 8 , indicating that patients with a notified occupational skin disease were more likely to respond. An explanation for this could be that those patients are more often seen by their dermatologist, so the CARPE visits do not represent an additional burden of assessment for them. This may also be the reason why the proportion of ACD was higher and the proportion of vesicular HE was lower in the responder group, which mirrors the diagnostic pattern in patients with occupational diseases notified in the CARPE registry (data not shown).
There is a large body of literature pertaining to HE, but little research has been conducted in CHE. The characteristics of patients included in the CARPE registry are largely in line with other data reported from studies performed in populations with CHE, all of which were non-interventional studies on alitretinoin. The TOCCATA study was the first study to investigate the treatment of CHE with oral alitretinoin in Germany, and included 680 patients with a mean age of 50 years. 22 In the TOCCATA study, 56% of the patients were male, the mean duration of CHE was 7 years, and CHE was graded as severe by PGA in 65% of patients. The real-world FUGETTA study investigated the impact of alitretinoin on HR-QoL in patients with CHE, and included 658 patients (52% male) with a mean age of 49 years. 23 Approximately 80% suffered from moderate-to-strong pruritus, and 83% of the CHE cases were rated as severe by PGA. In another real-world observational study, the PASSION study, 24 the mean age of the 631 included patients was 49 years, 48% of the patients were male, and 62% of CHE cases were rated as severe by PGA. Although, in terms of age, sex, and duration, the results are quite comparable, the severity seems to be slightly milder in the CARPE registry, in which 22.4% of patients were reported to have severe disease according to PGA, and 45.9% showed moderate severity.
The main findings of the descriptive analysis of the follow-up data presented in this article are as follows:
• Both objective disease severity and subjective disease severity decreased over time.
• HR-QoL improved over time, but remained stable after the second year of follow-up.
• The percentage of patients receiving systemic treatments (except antihistamines) decreased over time.
• The percentage of patients who reported side-effects or regarded the treatment as time-consuming decreased over time, while treatment satisfaction increased. • The percentage of patients not being able to put treatment recommendations into practice increased over time.
• Healthcare utilization as measured by visits to general practitioners and dermatologists decreased after inclusion in the CARPE registry.
The overall picture is that CHE improves substantially over time, whether considered clinically or from the patients' own perception.
Three main reasons may account for this finding. First, the regular visits may improve CHE through psychological effects of monitoring and feedback, which means that the CARPE registry itself has an interventional effect. Second, the regular visits also mean that there is room to optimize both treatment and the prevention of disease progression. Third, patients with difficult-to-treat CHE may have been more likely to have dropped out from the CARPE registry. On the other hand, the proportion of patients who reported not being able to fully implement treatment recommendations increased over time, which may indicate that patients with difficult-to-treat CHE are more likely to remain in the CARPE registry. In fact, both types of selection bias may operate at the same time. Either way, the loss to follow-up, particularly during the extended follow-up period after the second year, is a limitation of the CARPE registry. Another possible limitation may be the impact of large and highly specialized centres, which were overrepresented in the CARPE registry in comparison with their service share in the German health system. Some expensive or timeconsuming treatment regimens may be primarily prescribed in such specialized centres. For instance, the omission of data from the CARPE centre that contributed the largest number of patients means that the prescription rate of PUVA cream at T 0 decreased from 23.0% to 14.3%. Such aspects should be the focus of further reports on the CARPE data.
